JP5945278B2 - 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール - Google Patents

呼吸合胞体ウイルスの抗ウイルス剤としてのインドール Download PDF

Info

Publication number
JP5945278B2
JP5945278B2 JP2013543801A JP2013543801A JP5945278B2 JP 5945278 B2 JP5945278 B2 JP 5945278B2 JP 2013543801 A JP2013543801 A JP 2013543801A JP 2013543801 A JP2013543801 A JP 2013543801A JP 5945278 B2 JP5945278 B2 JP 5945278B2
Authority
JP
Japan
Prior art keywords
compound according
group
alkyl
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013543801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503525A (ja
JP2014503525A5 (https=
Inventor
コーイマン，ルートビヒ・ポール
ドマン，サミユエル・ドミニク
フー，リリ
ヨンカース，テイム・ヒユーゴ・マリア
ラボワソン，ピエール・ジヤン−マリー・ベルナール
ターリ，アブデラー
バンドビル，サンドリーヌ・マリー・エレーヌ
Original Assignee
ヤンセン・サイエンシズ・アイルランド・ユーシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・ユーシー filed Critical ヤンセン・サイエンシズ・アイルランド・ユーシー
Publication of JP2014503525A publication Critical patent/JP2014503525A/ja
Publication of JP2014503525A5 publication Critical patent/JP2014503525A5/ja
Application granted granted Critical
Publication of JP5945278B2 publication Critical patent/JP5945278B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013543801A 2010-12-16 2011-12-16 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール Expired - Fee Related JP5945278B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195468.3 2010-12-16
EP10195468 2010-12-16
PCT/EP2011/073011 WO2012080447A1 (en) 2010-12-16 2011-12-16 Indoles as respiratory syncytial virus antiviral agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016048038A Division JP2016145236A (ja) 2010-12-16 2016-03-11 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Publications (3)

Publication Number Publication Date
JP2014503525A JP2014503525A (ja) 2014-02-13
JP2014503525A5 JP2014503525A5 (https=) 2014-07-10
JP5945278B2 true JP5945278B2 (ja) 2016-07-05

Family

ID=43875270

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013543801A Expired - Fee Related JP5945278B2 (ja) 2010-12-16 2011-12-16 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール
JP2016048038A Pending JP2016145236A (ja) 2010-12-16 2016-03-11 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016048038A Pending JP2016145236A (ja) 2010-12-16 2016-03-11 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Country Status (31)

Country Link
US (3) US8921560B2 (https=)
EP (1) EP2651922B1 (https=)
JP (2) JP5945278B2 (https=)
KR (1) KR101914606B1 (https=)
CN (1) CN103347875B (https=)
AR (1) AR084335A1 (https=)
AU (1) AU2011343256C1 (https=)
BR (1) BR112013011949B1 (https=)
CA (1) CA2822000C (https=)
CL (1) CL2013001715A1 (https=)
CY (1) CY1117763T1 (https=)
DK (1) DK2651922T3 (https=)
EA (1) EA022339B1 (https=)
ES (1) ES2572258T3 (https=)
HR (1) HRP20160533T1 (https=)
HU (1) HUE028009T2 (https=)
IL (1) IL225641A (https=)
ME (1) ME02406B (https=)
MX (1) MX339944B (https=)
MY (1) MY163981A (https=)
NZ (1) NZ609487A (https=)
PH (1) PH12013500797A1 (https=)
PL (1) PL2651922T3 (https=)
RS (1) RS54746B1 (https=)
SG (1) SG189866A1 (https=)
SI (1) SI2651922T1 (https=)
SM (1) SMT201600142B (https=)
TW (1) TWI515187B (https=)
UA (1) UA109792C2 (https=)
WO (1) WO2012080447A1 (https=)
ZA (1) ZA201304423B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016145236A (ja) * 2010-12-16 2016-08-12 ヤンセン・サイエンシズ・アイルランド・ユーシー 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501967B (zh) * 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
US20150111868A1 (en) 2012-06-15 2015-04-23 Jansen R&D Ireland Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
JP2015519387A (ja) * 2012-06-15 2015-07-09 ヤンセン・アールアンドデイ・アイルランド Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
ES2600318T3 (es) * 2012-07-10 2017-02-08 F. Hoffmann-La Roche Ag Nuevos indazoles para el tratamiento y profilaxis de infección por virus sincitial respiratorio
MY172021A (en) 2012-10-16 2019-11-12 Janssen Sciences Ireland Uc Rsv antiviral compounds
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
PE20170673A1 (es) * 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
DK3324977T3 (da) 2015-07-22 2022-10-17 Enanta Pharm Inc Benzodiazepinderivater som rsv-inhibitorer
CN108473495B (zh) 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EP3411028B1 (en) 2016-02-03 2021-05-05 Janssen Sciences Ireland Unlimited Company Combination product for treating or ameliorating respiratory syncytial virus infection
CN109152368A (zh) 2016-03-15 2019-01-04 拜耳作物科学股份公司 用于防治动物害虫的取代的磺酰胺
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
TW201936193A (zh) 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
AU2020357452B2 (en) 2019-10-04 2026-01-29 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AU2020372633A1 (en) * 2019-10-30 2022-04-21 Janssen Sciences Ireland Unlimited Company Synthesis of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2 yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one
EP4051663B1 (en) * 2019-10-30 2024-02-21 Janssen Sciences Ireland Unlimited Company Synthesis of 3-nitro-n-(2,2,2-trifluoroethyl)-4-pyridinamine
US20220380318A1 (en) 2019-11-07 2022-12-01 Bayer Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
EP4165034A1 (en) * 2020-06-11 2023-04-19 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
CA3200111C (en) 2020-10-28 2025-02-18 Shionogi & Co., Ltd. AMIDE DERIVATIVE WITH ANTIVIRAL ACTIVITY
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2022184606A1 (en) 2021-03-01 2022-09-09 Janssen Sciences Ireland Unlimited Company Synthesis of rilematovir
CN114014856B (zh) * 2021-11-26 2023-12-22 嘉兴安谛康生物科技有限公司 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途
CN121648112B (zh) * 2026-02-04 2026-04-14 中国人民解放军陆军军医大学第二附属医院 一种苯并咪唑酮化合物在制备治疗椎间盘退变药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
IL147327A0 (en) 1999-06-28 2002-08-14 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
SI1196408T1 (en) 1999-06-28 2005-02-28 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
US6534535B1 (en) * 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001057019A1 (en) * 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
EP1255750A1 (en) * 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2003049688A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company Bis hydrochloride monohydrate salt of rsv fusion inhibitor
AU2002358219A1 (en) 2001-12-21 2003-07-15 Sense Proteomic Limited Protein analysis using mass spectrometry
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
PE20050068A1 (es) 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s
US7343930B2 (en) 2004-12-03 2008-03-18 Masco Corporation Of Indiana Sprayer with non-faucet control
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US9150556B2 (en) 2007-05-22 2015-10-06 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI530495B (zh) * 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI541241B (zh) * 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
CA2821367A1 (en) 2010-12-17 2012-06-21 Sanofi-Aventis Deutschland Gmbh Medicament administration
JP2015519387A (ja) 2012-06-15 2015-07-09 ヤンセン・アールアンドデイ・アイルランド Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
US20150111868A1 (en) 2012-06-15 2015-04-23 Jansen R&D Ireland Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
WO2013186334A1 (en) 2012-06-15 2013-12-19 Janssen R&D Ireland 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
EA201590023A1 (ru) 2012-06-15 2015-05-29 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
MY172021A (en) 2012-10-16 2019-11-12 Janssen Sciences Ireland Uc Rsv antiviral compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016145236A (ja) * 2010-12-16 2016-08-12 ヤンセン・サイエンシズ・アイルランド・ユーシー 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール

Also Published As

Publication number Publication date
UA109792C2 (uk) 2015-10-12
TWI515187B (zh) 2016-01-01
PL2651922T3 (pl) 2016-10-31
AR084335A1 (es) 2013-05-08
SI2651922T1 (sl) 2016-08-31
IL225641A0 (en) 2013-06-27
CN103347875A (zh) 2013-10-09
WO2012080447A1 (en) 2012-06-21
MX339944B (es) 2016-06-17
US20150073013A1 (en) 2015-03-12
AU2011343256C1 (en) 2015-08-13
US9321768B2 (en) 2016-04-26
ES2572258T3 (es) 2016-05-31
TW201307325A (zh) 2013-02-16
CL2013001715A1 (es) 2013-12-20
KR101914606B1 (ko) 2018-11-02
CA2822000A1 (en) 2012-06-21
CA2822000C (en) 2019-01-15
HRP20160533T1 (hr) 2016-07-01
ZA201304423B (en) 2014-12-23
EP2651922B1 (en) 2016-02-24
KR20140037800A (ko) 2014-03-27
JP2014503525A (ja) 2014-02-13
IL225641A (en) 2016-09-29
CY1117763T1 (el) 2017-05-17
SG189866A1 (en) 2013-07-31
US20160237083A1 (en) 2016-08-18
AU2011343256B2 (en) 2015-02-05
CN103347875B (zh) 2016-03-30
BR112013011949A2 (pt) 2016-08-23
HUE028009T2 (en) 2016-11-28
RS54746B1 (sr) 2016-10-31
ME02406B (me) 2016-09-20
PH12013500797A1 (en) 2013-06-24
AU2011343256A1 (en) 2013-05-02
JP2016145236A (ja) 2016-08-12
SMT201600142B (it) 2016-07-01
MY163981A (en) 2017-11-15
HK1185613A1 (zh) 2014-02-21
DK2651922T3 (en) 2016-05-30
NZ609487A (en) 2014-10-31
US8921560B2 (en) 2014-12-30
EP2651922A1 (en) 2013-10-23
EA201390883A1 (ru) 2013-10-30
US20130267555A1 (en) 2013-10-10
EA022339B1 (ru) 2015-12-30
US9944638B2 (en) 2018-04-17
BR112013011949B1 (pt) 2021-11-23
MX2013006887A (es) 2013-07-05

Similar Documents

Publication Publication Date Title
JP5945278B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのインドール
JP5876502B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのアザインドール
JP5876503B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのイミダゾピリジン
JP5876501B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのアザベンゾイミダゾール
JP6005656B2 (ja) ベンゾイミダゾール呼吸合胞体ウイルス阻害剤
JP6259451B2 (ja) Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
HK1185613B (en) Indoles as respiratory syncytial virus antiviral agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141215

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160311

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160527

R150 Certificate of patent or registration of utility model

Ref document number: 5945278

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees